Reaffirming India’s growing capability to develop and manufacture cutting-edge biologic therapies for the world

重申印度日益增长的为世界开发和制造尖端生物疗法的能力

image credit- freepik

图片来源：freepik

Pandorum Technologies, a clinical-stage regenerative medicine company building a next-generation platform for programmable tissue regeneration, has announced a strategic collaboration with Nucelion Therapeutics, a specialised contract research, development and manufacturing organisation (CRDMO), to expand manufacturing capabilities for Pandorum’s exosome-based therapeutic platform across the Asia-Pacific (APAC) region..

Pandorum Technologies是一家处于临床阶段的再生医学公司，正在构建一个用于可编程组织再生的下一代平台，该公司宣布与专门从事合同研究、开发和制造的组织（CRDMO）Nucelion Therapeutics达成战略协作，以扩大Pandorum基于外泌体的治疗平台在亚太地区（APAC）的制造能力。

This strategic collaboration aligns with a shared vision, as Pandorum’s asset(s) progress toward clinical trials. By leveraging Nucelion Therapeutics’ manufacturing capabilities, the partnership supports regional supply and regulatory readiness, marking a strategic step forward. Furthermore, it reaffirms India’s growing capability to develop and manufacture cutting-edge biologic therapies for the world..

这一战略性合作符合共同的愿景，因为Pandorum的资产正朝着临床试验迈进。通过利用Nucelion Therapeutics的生产能力，该合作伙伴关系支持区域供应和监管准备，标志着向前迈出了战略性的一步。此外，这再次证明了印度正在不断增强为世界开发和生产前沿生物疗法的能力。

While the current programmes span ocular surface injury and inflammatory corneal diseases, including Stevens–Johnson syndrome (SJS), Neurotrophic Keratitis, Pandorum plans to expand its disease modifying treatments to reverse degenerative changes of skin, pulmonary, and other organ systems, affected by inflammation, vascular pathologies and fibrosis.  .

虽然目前的项目涵盖了眼表损伤和炎症性角膜疾病，包括史蒂文斯-约翰逊综合征 (SJS)、神经营养性角膜炎，但Pandorum计划将其疾病修饰治疗扩展到逆转受炎症、血管病变和纤维化影响的皮肤、肺部及其他器官系统的退行性变化。

Nucelion Therapeutics is a wholly owned subsidiary of India-based Bharat Biotech, a leading vaccine and biotechnology companies. It will provide end-to-end manufacturing support, including process scale-up, GMP-compliant production, and quality control of pharmaceutical-grade exosomes derived from clinical-grade mesenchymal stem cells. .

Nucelion Therapeutics 是印度 Bharat Biotech 的全资子公司，Bharat Biotech 是一家领先的疫苗和生物技术公司。该公司将提供端到端的制造支持，包括工艺放大、符合 GMP 标准的生产以及来源于临床级间充质干细胞的药用级外泌体的质量控制。

Pandorum is pioneering a tunable exosome platform designed to reprogramme diseased tissues by precisely modulating intercellular communication pathways. The company’s approach is grounded in the principle that tissues are learnable, dynamic biological systems, and that controlled delivery of biologically encoded signals—via designer extracellular vesicles (exosome)can restore tissue structure and function in conditions driven by inflammation, fibrosis, and loss of regenerative capacity..

Pandorum正在开创一种可调节的外泌体平台，旨在通过精确调节细胞间通信通路来重新编程病变组织。该公司的方法基于一个原则，即组织是可学习的、动态的生物系统，而通过设计好的细胞外囊泡（外泌体）进行生物编码信号的可控传递，可以在由炎症、纤维化和再生能力丧失驱动的疾病状态下恢复组织结构和功能。